Evolus, Inc. (NASDAQ: NASDAQ:EOLS), a global performance beauty company, has released preliminary unaudited financial results for the fourth quarter and full-year 2024, indicating significant growth. The company reported a 30% increase in net revenue for Q4 2024, totaling $79.0 million, and a 32% rise for the full year, reaching $266.3 million. These figures align with the top end of Evolus's guidance and mark the fifth consecutive year of exceeding 30% revenue growth. With a current market capitalization of $665.51 million and an impressive gross profit margin of 69.94%,
Looking ahead, Evolus anticipates a 30% to 33% increase in net revenue for 2025, projecting between $345 million to $355 million. This forecast includes contributions from the upcoming launch of Evolysse™ Form and Evolysse™ Smooth, two injectable hyaluronic acid (HA) gels expected to account for 8-10% of the total revenue for 2025. Non-GAAP operating expenses for the year are estimated to be between $230 million and $240 million.
Evolus's growth trajectory is further highlighted by an increase in accounts purchasing its flagship product, Jeuveau®, with approximately 830 new accounts in Q4 2024, and over 2,900 new accounts throughout the year. The company's consumer loyalty program, Evolus Rewards, also saw a 40% growth in enrollment, ending the year with roughly 1.1 million consumers.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.